New Venturetec Annual Press Release

CLICK TO DOWNLOAD
New Venturetec: Results for the fiscal year 2014/15 per September 30, 2015

 

Steinhausen, November 11, 2015. New Venturetec closed the fiscal year 2014/15, ended September 30, 2015, with a gain of USD 14,998,112 or USD 3.00 per share, compared to a loss of USD 20,639,722 or USD 4.13 per share in the fiscal year 2013/14. The net asset value per share increased from USD 9.93 to USD 12.94 which equals 30.3% during the reporting period; in CHF respectively from CHF 9.48 to CHF 12.60 or 32.9%.

The main reason for the gain was the increase of the quoted share price of Osiris Therapeutics from USD 12.59 per share to USD 18.47 per share. The gain was reduced by the decrease of the valuation of the private company mPortal from USD 0.50 per share to USD 0.31 per share and the loss of the investment in Reverb Network in the reporting period. The details on the valuation of the portfolio companies are described in the annual report.

As of September 30, 2015, New Venturetec had three investments of which two investments valued higher than the investment costs and one is valued below investment costs. The total value of investments is USD 83,783,969 which results in an unrealized gain of USD 38,742,445 against the costs of the investments. As of September 30 2015, the largest position is Osiris Therapeutics (NASDAQ:OSIR) with 90.5% of total investments. The net asset value per September 30, 2015 is USD 64,682,737.

The advisory fees for the fiscal year 2014/15 are USD 636,254. The board remuneration for each of the two outside board member, for the reporting period was CHF 25'000.

The annual report, including financial statements for the reporting period can be downloaded from www.newventuretec.com/investors/reports.aspx. The agenda of the annual shareholders meeting held at 8.30am on December 4, 2015 is available on www.newventuretec.com.

 

About New Venturetec

New Venturetec is a publicly traded Swiss investment company (SIX: NEV) which holds participations in venture companies in the areas of biotechnology and technology which are domiciled in the USA.

The investment horizon should be 10 years or more. A shareholder is recommended to follow the development with interest and base an investment or disinvestment decision on results of the development of the portfolio companies rather than on the general capital market and the investors’ sentiment. Any investor should only invest in New Venturetec if he can afford the complete loss of the investment without having to change his lifestyle. Significant risk is involved and the timelines may exceed the expectations. In addition, the market of New Venturetec shares is very illiquid. The risks of venture investments are 100%. The total loss of the investment has to be considered as a realistic possibility.

For further information:

Yves Huwyler
Hinterbergstrasse 47
6312 Steinhausen
Tel: 041 740 26 26
info@newventuretec.com